You are here

BioTime, Inc.

Company Information
Address
1010 Atlantic Ave Ste 102
Alameda, CA 94501-1147
United States


http://www.biotimeinc.com

Information

DUNS: 781078977

# of Employees: 102


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    Amount: $385,923.00

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading t ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  2. Retinal tissue derived from human pluripotent stem cells for vision restoration

    Amount: $2,230,814.00

    Abstract from the original SBIR Phase II This project will test human embryonic stem cell derivedD retinal tissue transplanted in subretinal space ofanimal models with photoreceptorPRdegeneration in a ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  3. Cell Targeting Peptides for Isolating Patient Specific Stem Cells

    Amount: $224,911.00

    DESCRIPTION (provided by applicant): The ability of human pluripotent stem cells (hPS) to both self-renew and differentiate into virtually any cell type make them a promising source of cells for drug ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  4. SBIR Topic 314- High Content Screening of 3D Cultured Cancer Cells

    Amount: $285,423.00

    Not Available

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  5. Biodegradable, hyaluronic acid-based microcarriers for mesenchymal stem cell prop

    Amount: $335,900.00

    DESCRIPTION (provided by applicant): The emergence of human mesenchymal stem cell (hMSC)-based therapies requires the growth of a large number of viable, clinical grade hMSC for transplantation and th ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  6. Resuscitating Blood-Substituted Hypothermic Dogs

    Amount: $299,990.00

    DESCRIPTION (provided by applicant): Currently, due to high morbidity and mortality, the use of hypothermic circulatory arrest (HCA) is limited to only the most difficult surgical cases. During HCA ...

    STTRPhase I2004Department of Health and Human Services National Institutes of Health
  7. Resuscitating Blood-Substituted Hypothermic Dogs

    Amount: $299,990.00

    DESCRIPTION (provided by applicant): Currently, due to high morbidity and mortality, the use of hypothermic circulatory arrest (HCA) is limited to only the most difficult surgical cases. During HCA ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government